The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine. Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors. The study will last for about 10 months in total.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
56
Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
ICON - location Groningen
Groningen, Netherlands
Number of treatment emergent adverse events (TEAE)
Number of events
Time frame: From time of dosing (Day 1) to end of study (Day 14)
AUC0-t, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose
Hours\*micrometer (hr×µM)
Time frame: From pre-dose (Day 1) to end of exposure (Day 7)
AUC0-∞, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to infinity after a single dose
Hours\*micrometer (hr×µM)
Time frame: From pre-dose (Day 1) to end of exposure (Day 7)
Cmax, SD; the maximum plasma concentration of NNC6022 0001 after a single dose
Micrometer (µM)
Time frame: From pre-dose (Day 1) to end of exposure (Day 7)
IL-1β, SD; ratio of <Timepoint> (time of the maximal plasma concentration of NNC6022 0001) to baseline
Percentage (%)
Time frame: From pre-dose (Day 1) to estimated tmax (Day 1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.